Publicaties 2003 – 2008

149. Leurs PB, Van Oerle R, Hamulyak K, Wolffenbuttel BHR. Tissue factor pathway inhibitor (TFPI) release after heparin stimulation is increased in Type 1 diabetic patients with albuminuria. Diabet Med 2003; 20(1): 16-22.

150. Wolffenbuttel BHR, van der Klauw MM. [Psychiatric side effects associated with diphosphonate treatment]. Ned Tijdschr Geneeskd 2003; 147: 35-7.

151. van Breda E, Keizer HA, Kuipers H, Wolffenbuttel BHR. Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. Int J Sports Med 2003; 24: 195-6.

152. Eijkelberg IM, Spreeuwenberg C, Wolffenbuttel BHR, van Wilderen LJ, Mur-Veeman IM. Nurse-led shared care diabetes projects: lessons from the nurses’ viewpoint. Health Policy 2003; 66: 11-27.

153. De Clercq PA, Hasman A, Wolffenbuttel BHR. A consumer health record for supporting the patient-centered management of chronic diseases. Med Inform Internet Med 2003; 28: 117-27.

154. Schaars CF, Denig P, Kasje WN, Stewart RE, Wolffenbuttel BHR, Haaijer-Ruskamp FM. Physician, Organizational, and Patient Factors Associated With Suboptimal Blood Pressure Management in Type 2 Diabetic Patients in Primary Care. Diabetes Care 2004; 27: 123-128.

155. Rennenberg RJMW, Bravenboer B, Wolffenbuttel BHR. Het ‘empty sella’-syndroom als oorzaak van panhypopituïtarisme. Ned Tijdschr Geneeskd 2004; 148: 33-6

156. Hartog JW, Smit AJ, van Son WJ, Navis G, Gans RO, Wolffenbuttel BHR, de Jong PE. Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. Am J Kidney Dis 2004; 43(6): 966-75

157. van de Merbel NC, Mentink CJ, Hendriks G, Wolffenbuttel BHR. Liquid chromatographic method for the quantitative determination of N-epsilon-carboxymethyllysine in human plasma proteins. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 808(2): 163-8.

158. Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BHR, Koelendorf K, Friberg HH, Windfeld K, Lindholm A. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabet Med 2004; 21(7): 769-75.

159. Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BHR. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein(a). Br J Sports Med 2004; 38: 253-259

160. Keers JC, Links TP, Bouma J, Gans ROB, Maaten JC ter, Wolffenbuttel BHR, Sluiter WJ, Sanderman R. Do diabetologist recognise self-management problems in their patients? Diabetes Res Clin Pract 2004; 66: 157-161

161. Wouters RS, van den Ouweland JM, Pouwels JG, Wolffenbuttel BHR. [Missed hyperinsulinaemia in a patient with an insulinoma]. Ned Tijdschr Geneeskd 2005; 149(17): 944-6

162. Kerstens MN, Wolffenbuttel BHR, Dullaart RP. [Tissue-specific changes in cortisol metabolism and their potential role in the metabolic syndrome]. Ned Tijdschr Geneeskd 2005; 149(16): 871-6

163. Wolffenbuttel BHR, Franken AA, Vincent HH; THE DUTCH CORALL STUDY GROUP. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J Intern Med 2005; 257(6): 531-9

164. Borggreve SE, Hillege HL, Wolffenbuttel BHR, de Jong PE, Bakker SJ, van der Steege G, van Tol A, Dullaart RP. The Effect of CETP -629C>A Promoter Polymorphism on HDL Cholesterol is Dependent on Serum Triglycerides. J Clin Endocrinol Metab 2005; 90(7): 4198-204

165. Nuver J, Smit AJ, Wolffenbuttel BHR, Sluiter WJ, Hoekstra HJ, Sleijfer DT, Gietema JA. The Metabolic Syndrome and Disturbances in Hormone Levels in Long-Term Survivors of Disseminated Testicular Cancer. J Clin Oncol. 2005 Feb 28; [Epub ahead of print]

166. Heijckmann AC, Huijberts MS, Geusens P, de Vries J, Menheere PP, Wolffenbuttel BHR. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol 2005; 153: 23-9

167. Koopmans KP, Brouwers AH, De Hooge MN, Van der Horst-Schrivers AN, Kema IP, Wolffenbuttel BHR, De Vries EG, Jager PL. Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. J Nucl Med 2005; 46: 1240-3

168. Dolfing JG, Dubois EF, Wolffenbuttel BHR, ten Hoor-Aukema NM, Schweitzer DH. Different cycle ergometer outcomes in severely obese men and women without documented cardiopulmonary morbidities before bariatric surgery. Chest 2005; 128: 256-62

169. Kuribayashi I, Nomoto S, Massa G, Oostdijk W, Wit JM, Wolffenbuttel BHR, Shizuta Y, Honke K. Steroid 11-beta-hydroxylase deficiency caused by compound heterozygosity for a novel mutation, p.G314R, in one CYP11B1 allele, and a chimeric CYP11B2/CYP11B1 in the other allele. Horm Res 2005; 63: 284-93

170. Dullaart RP, Riemens SC, Meinardi JR, Wolffenbuttel BHR, Sluiter WJ. Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox. Scand J Clin Lab Invest 2005; 65: 523-31.

171. De Vries R, Wolffenbuttel BHR, Sluiter WJ, van Tol A, Dullaart RP. Post-heparin plasma lipoprotein lipase, but not hepatic lipase activity, is related to plasma adiponectin in type 2 diabetic patients and healthy subjects. Clin Lab 2005; 51: 403-9.

172. de Vries R, Perton FG, Dallinga-Thie GM, van Roon AM, Wolffenbuttel BHR, van Tol A, Dullaart RP. Plasma Cholesteryl Ester Transfer Is a Determinant of Intima-Media Thickness in Type 2 Diabetic and Nondiabetic Subjects: Role of CETP and Triglycerides. Diabetes 2005; 54: 3554-9.

173. Dolfing JG, Wolffenbuttel BHR, ten Hoor-Aukema NM, Schweitzer DH. Daily high doses of fluoxetine for weight loss and improvement in lifestyle before bariatric surgery. Obes Surg 2005; 15: 1185-9

174. Keers JC, Bouma J, Links TP, ter Maaten JC, Gans RO, Wolffenbuttel BHR, Sanderman R. One-year follow-up effects of diabetes rehabilitation for patients with prolonged self-management difficulties. Patient Educ Couns 2006; 60: 16-23

175. Meinardi JR, van den Berg G, Wolffenbuttel BH, Kema IP, Dullaart RP. Cyclical Cushing’s syndrome due to an atypical thymic carcinoid. Neth J Med 2006; 64: 23-7

176. Mentink CJ, Kilhovd BK, Rondas-Colbers GJ, Torjesen PA, Wolffenbuttel BHR. Time course of specific AGEs during optimised glycaemic control in type 2 diabetes. Neth J Med 2006; 64: 10-6

177. de Vries R, Dallinga-Thie GM, Smit AJ, Wolffenbuttel BHR, van Tol A, Dullaart RP. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006; 49: 398-404

178. Persoon AC, Links TP, Wilde J, Sluiter WJ, Wolffenbuttel BHR, van den Ouweland JM. Thyroglobulin (Tg) Recovery Testing with Quantitative Tg Antibody Measurement for Determining Interference in Serum Tg Assays in Differentiated Thyroid Carcinoma. Clin Chem 2006; 52(6): 1196-9

179. Persoon AC, Van Den Ouweland JM, Wilde J, Kema IP, Wolffenbuttel BHR, Links TP. Clinical utility of an automated immunochemiluminometric thyroglobulin assay in differentiated thyroid carcinoma. Clin Chem 2006; 52: 686-91

180. Hartog JW, de Vries AP, Bakker SJ, Graaff R, van Son WJ, Homan van der Heide JJ, Gans RO, Wolffenbuttel BHR, de Jong PE, Smit AJ. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Nephrol Dial Transplant 2006; 21(8): 2263-9

181. Borggreve SE, Hillege HL, Wolffenbuttel BHR, de Jong PE, Zuurman MW, van der Steege G, van Tol A, Dullaart RP; PREVEND Study Group. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006; 91(9): 3382-8

182. Nap RR, Meinardi JR, van den Berg G, Dullaart RP, de Vries J, Wolffenbuttel BHR. [Long-term follow-up is indicated after surgery for a phaeochromocytoma] Ned Tijdschr Geneeskd 2006; 150(19): 1045-9

183. van der Horst-Schrivers AN, Kerstens MN, Wolffenbuttel BHR. Preoperative pharmacological management of phaeochromocytoma. Neth J Med 2006; 64(8): 290-5 Review

184. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BHR. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007; 92(2): 491-6

185. de Groot JW, Plukker JT, Wolffenbuttel BHR, Wiggers T, Sluiter WJ, Links TP. Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf) 2006; 65(6): 729-36.

186. Groot JW, Kema IP, Breukelman H, Veer E, Wiggers T, Plukker JT, Wolffenbuttel BHR, Links TP. Biochemical Markers in the Follow-up of Medullary Thyroid Cancer. Thyroid 2006; 16(11): 1163-70

187. van den Bergh AC, van den Berg G, Schoorl MA, Sluiter WJ, van der Vliet AM, Hoving EW, Szabo BG, Langendijk JA, Wolffenbuttel BHR, Dullaart RP. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: Beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys 2007; 67(3): 863-9

188. Dullaart RP, Dallinga-Thie GM, Wolffenbuttel BHR, van Tol A. CETP inhibition in cardiovascular risk management: a critical appraisal. Eur J Clin Invest 2007; 37(2): 90-8

189. Alvarez-Llamas G, Szalowska E, de Vries MP, Weening D, Landman K, Hoek A, Wolffenbuttel BHR, Roelofsen H, Vonk RJ. Characterization of the human visceral adipose tissue secretome. Mol Cell Proteomics 2007; 6(4): 589-600

190. de Vries R, Groen AK, Perton FG, Dallinga-Thie GM, van Wijland MJ, Dikkeschei LD, Wolffenbuttel BHR, van Tol A, Dullaart RP. Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: Roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis 2007; 196(2): 733-41

191. Lely AT, Krikken JA, Bakker SJ, Boomsma F, Dullaart RP, Wolffenbuttel BHR, Navis G. Low dietary sodium and exogenous angiotensin II infusion decrease plasma adiponectin concentrations in healthy men. J Clin Endocrinol Metab 2007; 92(5): 1821-6

192. van Beek AP, van den Bergh AC, van den Berg LM, van den Berg G, Keers JC, Langendijk JA, Wolffenbuttel BHR. Radiotherapy is not associated with reduced quality of life and cognitive function in patients treated for nonfunctioning pituitary adenoma. Int J Radiat Oncol Biol Phys 2007; 68(4): 986-91

193. Borggreve SE, Hillege HL, Dallinga-Thie GM, de Jong PE, Wolffenbuttel BHR, Grobbee DE, van Tol A, Dullaart RP; PREVEND Study Group. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J 2007; 28(8): 1012-8

194. de Groot JW, Links TP, Sluiter WJ, Wolffenbuttel BHR, Wiggers T, Plukker JT. Locoregional control in patients with palpable medullary thyroid cancer: Results of standardized compartment-oriented surgery. Head Neck 2007; 29(9): 857-63

195. Bilo HJ, Logtenberg SJ, de Grauw WJ, Kleefstra N, Wolffenbuttel BHR. Time to move from serum creatinine to eGFR. Diabet Med. 2007 May;24(5):571-2; author reply 572-3

196. Bilo HJ, Logtenberg SJ, Dikkeschei LD, Kleefstra N, Wolffenbuttel BHR. [Assessment of renal function according to the NHG protocol ‘Diabetes mellitus type 2′: risk of overestimating the number of diabetes patients with renal dysfunction]. Ned Tijdschr Geneeskd 2007; 151(18): 1024-8 Dutch.

197. Phan HT, Jager PL, Plukker JT, Wolffenbuttel BHR, Dierckx RA, Links TP. Detection of bone metastases in thyroid cancer patients: bone scintigraphy or 18F-FDG PET? Nucl Med Commun 2007; 28(8): 597-602

198. Persoon AC, Jager PL, Sluiter WJ, Plukker JT, Wolffenbuttel BHR, Links TP. A sensitive Tg assay or rhTSH stimulated Tg: what’s the best in the long-term follow-up of patients with differentiated thyroid carcinoma? PLoS ONE 2007; 2(8): e816

199. Meinardi JR, Wolffenbuttel BHR, Dullaart RP. Cyclic Cushing’s syndrome: a clinical challenge. Eur J Endocrinol. 2007; 157(3): 245-54 Review

200. Wolffenbuttel BHR.[Doubts as to the cardiovascular safety of rosiglitazone] Ned Tijdschr Geneeskd. 2007; 151(40): 2236-7; author reply 2237

201. Noordzij MJ, de Heide LJ, Links TP, Jager PL, Wolffenbuttel BHR. [Four patients with incidentalomas of the thyroid discovered on 18-fluoro-deoxyglucose positron-emission tomography (FDG-PET)]. Ned Tijdschr Geneeskd 2007; 151(42): 2337-41

202. Bos MB, de Vries JH, Wolffenbuttel BHR, Verhagen H, Hillege JL, Feskens EJ. [The prevalence of the metabolic syndrome in the Netherlands: increased risk of cardiovascular diseases and diabetes mellitus type 2 in one quarter of persons under 60]. Ned Tijdschr Geneeskd 2007; 151(43): 2382-. Dutch

203. Heijckmann AC, Huijberts MS, De Vries J, Menheere PP, Van Der Veer E, Kruseman AC, Wolffenbuttel BHR, Geusens P, Drent M. Bone turnover and hip bone mineral density in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2007; 24(1): 51-8.

204. Voorham J, Haaijer-Ruskamp F, Denig P, Wolffenbuttel BHR, Stolk RP; Groningen Initiative to Analyse Type 2 Treatment (GIANTT) group.The influence of elevated cardiometabolic risk factor levels on treatment changes in type 2 diabetes. Diabetes Care 2008; 31(3): 501-3

205. Stolk RP, Rosmalen JG, Postma DS, de Boer RA, Navis G, Slaets JP, Ormel J, Wolffenbuttel BHR. Universal risk factors for multifactorial diseases : LifeLines: a three-generation population-based study. Eur J Epidemiol 2008; 23(1): 67-74

206. Phan HT, Jager PL, van der Wal JE, Sluiter WJ, Plukker JT, Dierckx RA, Wolffenbuttel BHR, Links TP. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol 2008; 158(1): 77-83.

207. Phan HT, Jager PL, Paans AM, Plukker JT, Sturkenboom MG, Sluiter WJ, Wolffenbuttel BHR, Dierckx RA, Links TP. The diagnostic value of (124)I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35(5): 958-65

208. Borggreve SE, de Vries R, Dallinga-Thie GM, Wolffenbuttel BHR, Groen AK, van Tol A, Dullaart RP. The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the -629C–>A cholesteryl ester transfer protein promoter polymorphism: Role of lecithin:cholesterol acyltransferase activity. Biochim Biophys Acta 2008; 1781(1-2): 10-5

209. Voorham J, Denig P, Wolffenbuttel BHR, Haaijer-Ruskamp FM. Cross-Sectional Versus Sequential Quality Indicators of Risk Factor Management in Patients with Type 2 Diabetes. Med Care 2008; 46(2): 133-141

210. Meeuwisse-Pasterkamp SH, van der Klauw MM, Wolffenbuttel BHR. Type 2 diabetes mellitus: prevention of macrovascular complications.Expert Rev Cardiovasc Ther 2008; 6(3): 323-41

211. Heijckmann AC, Drent M, Dumitrescu B, De Vries J, Nieuwenhuijzen Kruseman AC, Wolffenbuttel BHR, Geusens P, Huijberts MS. Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study. Osteoporos Int 2008; 19: 839-47

212. Heijckmann AC, Dumitrescu B, Nieuwenhuijzen Kruseman AC, Geusens P, Wolffenbuttel BH, De Vries J, Drent M, Huijberts MS.Quantitative ultrasound does not identify patients with an inflammatory disease at risk of vertebral deformities. BMC Musculoskelet Disord 2008; 9: 72.

213. Koolhaas W, Prak A, Stiekema HM, Kreeftenberg HG, Wolffenbuttel BH, Jager PL.[Efficient and improved diagnosis of osteoporosis by simultaneous bone density measurement and spinal morphometry]. Ned Tijdschr Geneeskd 2008; 152: 938-43. Dutch.

214. Penning-van Beest FJ, Wolffenbuttel BH, Herings RM. Haemoglobin A1c goal attainment in relation to dose in patients with diabetes mellitus taking metformin: a nested, case-control study. Clin Drug Investig. 2008; 28(8): 487-93.

215. Heijckmann AC, Huijberts MS, Schoon EJ, Geusens P, de Vries J, Menheere PP, van der Veer E, Wolffenbuttel BHR, Stockbrugger RW, Dumitrescu B, Nieuwenhuijzen Kruseman AC. High prevalence of morphometric vertebral deformities in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008; 20: 740-7.

216. Phan HT, Jager PL, Plukker JT, Wolffenbuttel BH, Dierckx RA, Links TP. Comparison of 11C-methionine PET and 18F-fluorodeoxyglucose PET in differentiated thyroid cancer. Nucl Med Commun 2008; 29: 711-6.

217. Ross HA, Menheere PP; (on behalf of the Endocrinology Section of SKML [Dutch Foundation for Quality Assessment in Clinical Laboratories]), Thomas CM, Mudde AH, Kouwenberg M, Wolffenbuttel BHR. Interference from heterophilic antibodies in seven current TSH assays. Ann Clin Biochem 2008; 45(Pt 6): 616. Epub 2008 Sep 9.

218. Bangma HR, Smit GP, Kuks JB, Grevink RG, Wolffenbuttel BHR. [Two patients with mitochondrial respiratory chain disease]. Ned Tijdschr Geneeskd 2008; 152: 2298-301. Dutch.

219. Wolffenbuttel BH, van den Berg G, Hoving EW, van der Klauw MM. [The natural course of non-functioning pituitary adenomas]. Ned Tijdschr Geneeskd 2008; 152: 2537-43. Dutch